RESUMO
Organizing pneumonia is a nonspecific pulmonary response pattern associated with a variety of clinical contexts including viral infections. The classic radiological manifestations are peribronchovascular/peripheral ground glass opacities or consolidations and may be accompanied by nodules, masses, and interstitial opacities. We describe the case of a 62-year-old male patient with SARS-CoV-2 pneumonia and torpid clinical and radiological evolution in whom organizing pneumonia was documented through transbronchial biopsy and imaging findings, with a good response to corticosteroids. The importance of recognizing the development of organizing pneumonia lies in the better prognosis and outcome in those patients who receive treatment with corticosteroids, however, the clinical and radiological suspicion must be confirmed with biopsy because radiological findings associated with bacterial coinfection may overlap.
RESUMO
resumen está disponible en el texto completo
Abstract Recent studies have reported the occurrence of thrombotic phenomena or coagulopathy in patients with COVID-19. There are divergent positions regarding the prevention, diagnosis, and treatment of these phenomena, and current clinical practice is based solely on deductions by extension from retrospective studies, case series, observational studies, and international guidelines developed prior to the pandemic. In this context, the aim was to generate a group of recommendations on the prevention, diagnosis and management of thrombotic complications associated with COVID-19. Methods: A rapid guidance was carried out applying the GRADE Evidence to Decision (EtD) frameworks and an iterative participation system, with statistical and qualitative analysis. Results: 31 clinical recommendations were generated focused on: a) Coagulation tests in symptomatic adults with suspected infection or confirmed SARS CoV-2 infection; b) Thromboprophylaxis in adults diagnosed with COVID-19 (Risk scales, thromboprophylaxis for outpatient, in-hospital management, and duration of thromboprophylaxis after discharge from hospitalization), c) Diagnosis and treatment of thrombotic complications, and d) Management of people with previous indication of anticoagulant agents. Conclusions: Recommendations of this consensus guide clinical decision-making regarding the prevention, diagnosis, and treatment of thrombotic phenomena in patients with COVID-19, and represent an agreement that will help decrease the dispersion in clinical practices according to the challenge imposed by the pandemic.
